UPDATE: Raymond James Downgrades Jounce Therapeutics (JNCE) to Outperform
Tweet Send to a Friend
(Updated - November 10, 2022 4:45 PM EST)
Raymond James analyst Steven Seedhouse downgraded Jounce Therapeutics (NASDAQ: JNCE) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Raymond James analyst Steven Seedhouse downgraded Jounce Therapeutics (NASDAQ: JNCE) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
